0.26  0 (0%)		07-01 15:33
Open: 0.261 High: 0.261 Volume: 2,157		Pre. Close: 0.26 Low: 0.26 Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	0.36	1-year :	0.39
Resists	First :	0.3	Second :	0.34
Pivot price	0.28
Supports	First :	0.25	Second :	0.21
MAs	MA(5) :	0.29	MA(20) :	0.29
	MA(100) :	0.31	MA(250) :	0.92
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	33.3	D(3) :	44.7
RSI	RSI(14): 44.6
52-week	High :	8.27	Low :	0.23

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ XAGE ] has closed above bottom band by 29.0%. Bollinger Bands are 25.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.26 - 0.26	0.26 - 0.26
Low:	0.26 - 0.26	0.26 - 0.26
Close:	0.26 - 0.26	0.26 - 0.26

Longevity Health Holdings Inc. specializes in creating plasma-based bioactive materials (PBMs) aimed at fostering tissue regeneration and repair in response to injury, illness, and the natural aging process. The company's primary investigational product is CT-101, which acts as a powerful accelerant for bone healing in diverse applications such as tibia fracture recovery, foot/ankle and spinal fusions, serving as a dental bone graft substitute, and filling bone voids. Additionally, CT-101 functions as a tissue healing accelerant, offering potential for treating androgenetic alopecia and persistent chronic wounds. Established in 2008, the company maintains its headquarters in Pittsburgh, Pennsylvania.

Tue, 17 Mar 2026
Longevity Health Holdings Closes Strategic Investment and - GlobeNewswire

Tue, 19 Aug 2025
Kendra Bracken Ferguson Net Worth (2026) - GuruFocus

Mon, 14 Jul 2025
Longevity Health Holdings Announces Merger with THPlasma and Termination of 20/20 BioLabs Transaction - GlobeNewswire

Thu, 10 Jul 2025
20/20 BioLabs' public debut stalls as merger with Longevity Health collapses - The Business Journals

Thu, 24 Apr 2025
XAGE Stock Price, News & Analysis - Stock Titan

Mon, 14 Apr 2025
Longevity Health Holdings Announces Execution of Merger Agreement With 20/20 Biolabs - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: OTC
Sector: Healthcare
Industry: Biotechnology
Shares Out	2 (M)
Shares Float	2 (M)
Held by Insiders	36 (%)
Held by Institutions	0.7 (%)
Shares Short	9 (K)
Shares Short P.Month	25 (K)

EPS	-4.06
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-2.24
Profit Margin	0 %
Operating Margin	-389.4 %
Return on Assets (ttm)	-170.2 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	-23.3 %
Gross Profit (p.s.)	0.48
Sales Per Share	0.72
EBITDA (p.s.)	-2.71
Qtrly Earnings Growth	0 %
Operating Cash Flow	-3 (M)
Levered Free Cash Flow	-1 (M)

PE Ratio	-0.07
PEG Ratio	0
Price to Book value	-0.12
Price to Sales	0.36
Price to Cash Flow	-0.22

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.